| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Division of Molecular and Surgical Oncology, Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
ABSTRACT
Purpose: For the development of peptide-based, cancer-specific immunotherapy, the identification of CTL epitopes from additional tumor antigens is very important. NY-ESO-1, a cancer–testis antigen, is considered to be a promising target of tumor-specific immunotherapy. Because HLA-A24-expressing individuals cover >60% in the population of Japan, we aim at identifying NY-ESO-1-encoded peptide presented by HLA-A24.
Experimental Design: In our study, a HLA-A24-restricted CTL epitope was identified by using the following four-step procedure: (a) computer-based epitope prediction from the amino acid sequence of NY-ESO-1 antigen; (b) peptide-binding assay to determine the affinity of the predicted peptide with HLA-A24 molecule; (c) stimulation of primary T-cell response against the predicted peptides in vitro; and (d) testing of the induced CTLs toward various carcinoma cells expressing NY-ESO-1 antigen and HLA-A24.
Results: Of the tested peptides, effectors induced by a peptide of NY-ESO-1 at residue position 158–166 lysed three kinds of carcinoma cells expressing both NY-ESO-1 and HLA-A24. Our results indicate that peptide NY-ESO-1 (158–166) (LLMWITQCF) is a new HLA-A24-restricted CTL epitope capable of inducing NY-ESO-1-specific CTLs in vitro mediating HLA class I-restricted manner.
Conclusions: We identified a novel HLA-A24-restricted NY-ESO-1-derived epitope peptide (LLMWITQCF) that could induce specific CTLs from the peripheral blood mononuclear cells of HLA-A24+ healthy donors. This peptide would be useful in further evaluating the clinical utility of peptide-based, cancer-specific immunotherapy against various histological tumors.
This article has been cited by other articles:
|
|
 |
|
  K. Odunsi, F. Qian, J. Matsuzaki, P. Mhawech-Fauceglia, C. Andrews, E. W. Hoffman, L. Pan, G. Ritter, J. Villella, B. Thomas, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer PNAS, July 31, 2007; 104(31): 12837 - 12842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hasegawa, Y. Noguchi, F. Koizumi, A. Uenaka, M. Tanaka, M. Shimono, H. Nakamura, H. Shiku, S. Gnjatic, R. Murphy, et al. In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15-Binding CD4 T-Cell Epitope Clin. Cancer Res., March 15, 2006; 12(6): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miyahara, H. Naota, L. Wang, A. Hiasa, M. Goto, M. Watanabe, S. Kitano, S. Okumura, T. Takemitsu, A. Yuta, et al. Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGE Clin. Cancer Res., August 1, 2005; 11(15): 5581 - 5589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Utsunomiya, H. Inoue, F. Tanaka, H. Yamaguchi, M. Ohta, M. Okamoto, K. Mimori, and M. Mori Expression of Cancer-Testis Antigen (CTA) Genes in Intrahepatic Cholangiocarcinoma Ann. Surg. Oncol., October 1, 2004; 11(10): 934 - 940. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
